HCW Biologics Inc
HCWB1.060USD
+0.020+1.92%
Horário de mercado （ET）Cotações atrasadas em 15 min
2.78MValor de mercado
PerdaP/L TTM
Mais detalhes de HCW Biologics Inc Empresa
HCW Biologics Inc. is a clinical-stage biopharmaceutical company. It is focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases, such as cancer, cardiovascular diseases, diabetes, neurodegenerative diseases, autoimmune diseases, as well as other conditions. It has developed a Tissue factOr-Based fusion (TOBI) discovery platform to generate designer, novel multi-functional fusion molecules with immunotherapeutic properties. Its lead product candidates include HCW9218 and HCW9302. HCW9218 is a clinical-stage bifunctional molecule that is designed to impact senescence by reducing senescent cells. The Company is prepared to progress HCW9218 in Phase II clinical trials for non-oncology indications.HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes. Its other product candidates include HCW9201, HCW9206, HCW11-006, and others.
Informações de HCW Biologics Inc
Código da empresaHCWB
Nome da EmpresaHCW Biologics Inc
Data de listagemJul 20, 2021
CEOWong (Hing C)
Número de funcionários36
Tipo de títulosOrdinary Share
Fim do ano fiscalJul 20
Endereço2929 N Commerce Pkwy
CidadeMIRAMAR
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal33025
Telefone19548422024
Sitehttps://hcwbiologics.com/
Código da empresaHCWB
Data de listagemJul 20, 2021
CEOWong (Hing C)
Executivos da empresa HCW Biologics Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Hing C. Wong, Ph.D.
Dr. Hing C. Wong, Ph.D.
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
501.91K
-8054.00%
Ms. Rebecca Byam
Ms. Rebecca Byam
Chief Financial Officer
Chief Financial Officer
43.01K
--
Mr. Scott T. Garrett
Mr. Scott T. Garrett
Independent Chairman of the Board
Independent Chairman of the Board
25.50K
--
Mr. Lee Flowers
Mr. Lee Flowers
Senior Vice President - Business Development
Senior Vice President - Business Development
5.72K
+962.00%
Dr. Peter Rhode, Ph.D.
Dr. Peter Rhode, Ph.D.
Chief Scientific Officer, Vice President - Clinical Operations
Chief Scientific Officer, Vice President - Clinical Operations
1.94K
--
Ms. Lisa M. Giles
Ms. Lisa M. Giles
Independent Director
Independent Director
896.00
--
Mr. Rick S. Greene
Mr. Rick S. Greene
Independent Director
Independent Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. Hing C. Wong, Ph.D.
Dr. Hing C. Wong, Ph.D.
Chief Executive Officer, Founder, Director
Chief Executive Officer, Founder, Director
501.91K
-8054.00%
Ms. Rebecca Byam
Ms. Rebecca Byam
Chief Financial Officer
Chief Financial Officer
43.01K
--
Mr. Scott T. Garrett
Mr. Scott T. Garrett
Independent Chairman of the Board
Independent Chairman of the Board
25.50K
--
Mr. Lee Flowers
Mr. Lee Flowers
Senior Vice President - Business Development
Senior Vice President - Business Development
5.72K
+962.00%
Dr. Peter Rhode, Ph.D.
Dr. Peter Rhode, Ph.D.
Chief Scientific Officer, Vice President - Clinical Operations
Chief Scientific Officer, Vice President - Clinical Operations
1.94K
--
Ms. Lisa M. Giles
Ms. Lisa M. Giles
Independent Director
Independent Director
896.00
--
Detalhamento da receita
Os dados relevantes ainda não foram divulgados pela empresa.
Os dados relevantes ainda não foram divulgados pela empresa.
Por Empresa
Por Região
Os dados relevantes ainda não foram divulgados pela empresa.
Distribuição de ações
Atualizado em: qua, 4 de fev
Atualizado em: qua, 4 de fev
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Wong (Hing C)
18.58%
DRW Securities, LLC
3.09%
Byam (Rebecca)
1.59%
Garrett (Scott T)
0.94%
The Vanguard Group, Inc.
0.57%
Outro
75.23%
Investidores
Investidores
Proporção
Wong (Hing C)
18.58%
DRW Securities, LLC
3.09%
Byam (Rebecca)
1.59%
Garrett (Scott T)
0.94%
The Vanguard Group, Inc.
0.57%
Outro
75.23%
Tipos de investidores
Investidores
Proporção
Individual Investor
21.71%
Investment Advisor
4.09%
Investment Advisor/Hedge Fund
0.41%
Research Firm
0.07%
Hedge Fund
0.06%
Outro
73.65%
Participação acionária institucional
Atualizado em: qui, 1 de jan
Atualizado em: qui, 1 de jan
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q4
36
125.21K
4.63%
+21.18K
2025Q3
35
36.93K
1.72%
-55.99K
2025Q2
40
613.16K
31.10%
+79.16K
2025Q1
40
480.61K
42.86%
-46.33K
2024Q4
37
23.10M
51.86%
+2.14M
2024Q3
33
21.13M
54.31%
+156.07K
2024Q2
33
21.19M
54.45%
+322.27K
2024Q1
34
20.93M
57.88%
+1.69M
2023Q4
33
19.30M
53.71%
+122.06K
2023Q3
33
19.17M
53.35%
-2.58K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Wong (Hing C)
509.96K
18.88%
+108.61K
+27.06%
May 16, 2025
DRW Securities, LLC
83.44K
3.09%
+83.44K
--
Sep 30, 2025
Byam (Rebecca)
43.01K
1.59%
+8.46K
+24.49%
May 12, 2025
Garrett (Scott T)
25.50K
0.94%
+18.81K
+280.84%
May 16, 2025
The Vanguard Group, Inc.
15.43K
0.57%
+15.43K
--
Sep 30, 2025
Geode Capital Management, L.L.C.
11.00K
0.41%
+11.00K
--
Sep 30, 2025
Golden State Wealth Management, LLC
10.00K
0.37%
--
--
Sep 30, 2025
Flowers (Lee)
5.72K
0.21%
+962.00
+20.23%
May 08, 2025
Winer (Gary M)
4.08K
0.15%
+3.65K
+858.82%
May 16, 2025
Greene (Rick Scott)
2.07K
0.08%
+962.00
+87.14%
May 12, 2025
Ver Mais
ETFs Relacionados
Atualizado em: sáb, 6 de dez
Atualizado em: sáb, 6 de dez
Nome
Proporção
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Apr 01, 2025
Merger
40→1
Data
Data ex-dividendo
Tipo
Proporção
Apr 01, 2025
Merger
40→1
